3
Announcements
Trials
Browse
Landscape
Status
Completed
1
Sponsor Class
OTHER
1
Study Type
Observational
1
Sponsor
Cancer Type
Genitourinary
3
Thoracic
2
Breast
2
Sarcoma
1
Lymphoid
1
Gynecologic
1
Gastrointestinal
1
Conditions
Lymphoma
2
Sarcoma
1
Prostatic Neoplasms
1
Ovarian Neoplasms
1
Multiple Myeloma
1
Mixed Dementias
1
Lymphoma, Follicular
1
Lung Neoplasms
1
Lewy Body Disease
1
Kidney Neoplasms
1
Dementia, Vascular
1
Dementia
1
Colorectal Neoplasms
1
Cognitive Dysfunction
1
Breast Neoplasms
1
Interventions
Vorinostat
3
Azacitidine
3
venetoclax
2
trametinib
2
ruxolitinib
2
pertuzumab
2
palbociclib
2
olaparib
2
durvalumab
2
dabrafenib
2
copanlisib
2
aflibercept
2
abiraterone
2
Sunitinib
2
Specimen Handling
2
Sirolimus
2
Nivolumab
2
Immunoglobulin G
2
HhAntag691
2
Doxorubicin
2
Disulfides
2
Dasatinib
2
Cyclophosphamide
2
Biopsy
2
Afatinib
2
Ado-Trastuzumab Emtansine
2
2C4 antibody
2
ulixertinib
1
tremelimumab
1
trastuzumab biosimilar HLX02
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Prostatic Neoplasms
×
Referral and Consultation
×
Lymphoid
×
Clear all
NCT02821793
2025-07-01
PRIORITY
Institut Bergonié
Completed
346 enrolled
9 charts